Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections

Vancouver, Canada, Feb. 07, 2022 (GLOBE NEWSWIRE) — Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare system tens of billions of dollars a year. [1] Ondine Biomedical Inc. (LON: OBI), has treated the first patients in its nasal photodisinfection exploratory Phase 2 trial. The study will evaluate how effectively the treatment eradicates pathogens – Staphylococcus aureus – in the nose, and the occurrence of surgical site infections